Progression of retinopathy after improved metabolic control in type 2 diabetic patients: Relation to IGF-1 and hemostatic variables

Diabetes Care

Volumn 22, Issue 12, 1999, Pages 1944-1949

  Henricsson, Marianne ^a,b   Berntorp, Kerstin ^a   Berntorp, Erik ^a   Fernlund, Per ^a   Sundkvist, Göran ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Department of Ophthalmology ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC RETINOPATHY; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOSTASIS; HUMAN; INSULIN TREATMENT; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RATING SCALE;

EID: 0033364506     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.12.1944     Document Type: Article

References (37)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 352:837-853, 1998
4. Dahl-Jorgensen K, Brinchmann-Hansen O, Hanssen KF, Sandvik L, Aagenaes O, Aker Diabetes Group: Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin-dependent diabetes mellitus: the Oslo study. Br Med J 290:811-815, 1985
5. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T: The Steno Study Group: two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 34 (Suppl. 3):74-79, 1985
6. Kroc Collaborative Study Group: Diabetic retinopathy after two years of intensified insulin treatment. JAMA 260:37-41, 1988
7. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF: Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo Study. Br Med J 304:19-22, 1992
8. Agardh C-D, Eckert B, Agardh E: Irreversible progression of severe retinopathy in young type 1 insulin-dependent diabetes mellitus patients after improved metabolic control. J Diabetes Complications 6: 96-100, 1992
9. Moskalets E, Galstyan G, Starostina E, Antsiferov M, Chantelau E: Association of blindness to intensification of glycemic control in insulin-dependent diabetes mellitus. J Diabetes Complications 8:45-50, 1994
10. Roysarkar TK, Gupta A, Dash RJ, Dogra MR: Effect of insulin therapy on progression of retinopathy in non-insulin-dependent diabetes mellitus. Am J Ophthalmol 115:569-574, 1993
11. Henricsson M, Janzon L, Groop L: Progression of retinopathy after change of treatment from oral antihyperglycemic agents to insulin in patients with non-insulin-dependent diabetes mellitus Diabetes Care 18: 1571-1576, 1995
12. Henricsson M, Nilsson A, Janzon L, Groop L: The effect of glycaemic control and the introduction of insulin therapy on retinopathy in non-insulin-dependent diabetes mellitus. Diabet Med 14:123-131, 1997
13. The Diabetes Control and Complications Trial Research Group: Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 116:874-886, 1998
14. LeRoith D: Insulin-like growth factors. N Engl J Med 336:633-640, 1997
15. Sundkvist G, Lilja B, Alḿer LO: Absent elevations in growth hormone, factor VIII related antigen, and plasminogen activator activity during exercise in diabetic patients resistant to retinopathy. Diabetes Res 7:25-30, 1988
16. Lundbaek K: Growth hormone's role in diabetic microangiopathy. Diabetes 25 (Suppl. 2): 845-849, 1976
17. Barnes AJ, Kohner EM, Johnston DG, Alberti KGMM: Severe retinopathy and mild carbohydrate intolerance: possible role of insulin deficiency and elevated circulating growth hormone. Lancet 29:1465-1468, 1985
18. Merimee TJ, Zapf J, Froesch ER: Insulin-like growth factors: studies in diabetics with and without retinopathy. N Engl J Med 309: 527-530, 1983
19. Chantelau E, Seppel T, Althaus C. Schönau E: Elevation of serum IGF-1 rather than sex steroids precedes proliferative retinopathy in Mauriac's syndrome. Horm Res 48:131-134, 1997
20. Chantelau E: Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy. Br J Ophthalmol 82:725-730, 1998
21. Ceriello A: Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 36:1119-1125, 1993
22. Berntorp K, Berntorp E: Resistance to activated protein C and coagulation risk factors, in type 1 and type 2 diabetes, in relation to micro- and macro-angiopathy Diabetes Res, 32:147-158, 1997
23. Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V: Relationships between diabetes duration, metabolic control and β-cell function in a representative population of type 2 diabetic patients. Diabet Med 11: 794-801, 1994
24. Gottsäter A, Landin-Olsson M, Fernlund P, Gullberg B, Lernmark Å, Sundkvist G: Pancreatic beta-cell function evaluated by intravenous glucose and glucagon stimulation: a comparison between insulin and C-peptide to measure insulin secretion. Scand J Clin Lab Invest 52:631-639, 1992
25. lc by a new liquid-chromatographic assay: methodology, clinical utility, and relation to glucose tolerance evaluated. Clin Chem 32:1867-1872, 1986
26. Zöller B, Svensson PJ, He X, Dahlbäck B: Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 94:2521-2524, 1994
27. Holmberg L, Berntorp E, Dornnér M, Nilsson IM: von Willebrand's disease characterized by increased ristocetin sensitivity and the presence of all von Willebrand factor multimers in plasma. Blood 68:668-672, 1986
28. Klein R, Klein BEK, Magli YL, Brothers RJ, Meuer SM, Davis MD: An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183-1187, 1986
29. Klein R. Klein BEK, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy IX: four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 107:237-243, 1989
30. Ferns FL, Kassoff A, Bresnick GH: New visual acuity charts for clinical research. Am J Ophthalmol 94:91-96, 1982
31. Matthews JNS, Altman DC, Campbell MJ, Royston P: Analysis of serial measurements in medical research. BMJ 300:230-235, 1990
32. Hyer SL, Sharp PS, Sleightholm M, Burrin JM, Kohner EM: Progression of diabetic retinopathy and changes in scrum insulin-like growth factor 1 (IGF 1) during continuous subcutaneous insulin infusion (CSII). Horm Metabolic Res 21:18-22, 1989
33. Wang Q, Dills DG, Klein R, Klein BEK, Moss SE: Does insulin-like growth factor 1 predict incidence and progression of retinopathy? Diabetes 44:161-164, 1995
34. Hyer SL, Sharp PS, Brooks RA, Burnn JM, Kohner EM: A two-year follow-up study of serum insulinlike growth factor-1 in diabetes with retinopathy. Metab Clin Exp 38: 586-589, 1989
35. Clauson PG. Brismar K, Hall K, Linnarsson R, Grill V: Insulin-like growth factor-1 and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58:353-360, 1998
36. Bauer KA, Weiss I.M, Sparrow D, Vokonas PS, Rosenberg RD: Aging-associated changes in indices of thrombin generation and protein C activation in humans. J Clin Invest 80: 1527-1534, 1987
37. Knöbl P, Schernthaner G, Schnack C, Pietschmann P, Griesmacher A, Prager R, Muller M: Thrombogenic factors are related to urinary albumin excretion rate in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:1045-1050, 1993